PROCEPT BioRobotics (US:PRCT) Globenewswire·2026-02-25 21:02Core Insights - PROCEPT BioRobotics Corporation reported a strong fourth quarter for 2025, achieving its highest procedure volume to date with approximately 12,200 procedures and selling 65 new systems, indicating robust growth and operational improvements [2][12]. Financial Performance - Total revenue for Q4 2025 was $76.4 million, a 12% increase compared to Q4 2024. U.S. revenue was $66.6 million, reflecting a 10% growth year-over-year, primarily driven by increased handpiece revenue [4][12]. - U.S. handpiece and consumable revenue reached $34.0 million, up 16% from the previous year, while system revenue remained flat at $27.6 million [4][12]. - The gross margin for Q4 2025 was 61%, down from 64% in the prior year, mainly due to lower-than-expected U.S. consumable revenue and a one-time cost related to a voluntary field action [5]. - Operating expenses for Q4 2025 were $77.4 million, an increase of 22% from $63.4 million in Q4 2024, reflecting investments in commercial expansion and R&D [6][9]. - The net loss for Q4 2025 was $29.8 million, compared to a loss of $18.9 million in Q4 2024. Adjusted EBITDA was a loss of $19.0 million, worsening from a loss of $10.3 million in the prior year [7][10]. Annual Overview - For the full year 2025, total revenue was $308.1 million, a 37% increase from 2024, driven by U.S. revenue growth from system placements and handpiece sales [8]. - The gross margin for the full year improved to 64% from 61% in 2024, attributed to better overhead absorption and a favorable revenue mix [8]. - Operating expenses for the full year were $300.1 million, up 28% from $233.7 million in 2024, due to increased sales and marketing expenses [9]. - The net loss for 2025 was $95.6 million, slightly higher than the $91.4 million loss in 2024. Adjusted EBITDA loss was $50.2 million, an improvement from a loss of $61.1 million in 2024 [10]. Future Guidance - The company expects 2026 revenue to be between $390 million and $410 million, representing a growth of 27% to 33% compared to 2025. U.S. procedure growth is projected to be between 39% and 48% [11][18]. - The anticipated gross margin for 2026 is approximately 65%, with operating expenses expected to be around $350 million [18]. - The company aims to align handpiece unit sales closely with procedure volumes, which may impact projected handpiece revenue but is expected to be offset by higher handpiece prices [11][18].